Vascular Inflammation in Psoriasis Trial (The VIP Trial)

PHASE4CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 8, 2016

Study Completion Date

October 27, 2016

Conditions
PsoriasisCardiovascular Disease
Interventions
DRUG

Adalimumab (Humira)

Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.

DRUG

Placebo Injection

Placebo injection will be given according to the same dose and schedule as the active comparator.

OTHER

NB-UVB phototherapy

Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.

Trial Locations (9)

14221

Buffalo Medical Group, Buffalo

19140

The University of Pennsylvania, Philadelphia

20892

National Heart, Lung, and Blood Institute, Bethesda

75246

Menter Dermatology Research Institute, Dallas

77004

Center for Clinical Studies, Houston

80045

The University of Colorado, Denver

84132

University of Utah, Salt Lake City

95816

University of California, Davis Health System, Sacramento

97239

Oregon Health & Science University, Portland

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT01553058 - Vascular Inflammation in Psoriasis Trial (The VIP Trial) | Biotech Hunter | Biotech Hunter